PMID: 9660361Jul 11, 1998Paper

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

JAMA : the Journal of the American Medical Association
R M GulickD D Richman

Abstract

Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients. To compare the antiretroviral effect of a 3-drug regimen started simultaneously or sequentially in patients with HIV infection. A multicenter, randomized, double-blind study, modified after at least 24 weeks of blinded therapy to provide open-label 3-drug therapy with follow-up through 100 weeks. Four clinical research units Ninety-seven patients with HIV infection who had taken zidovudine for at least 6 months with serum HIV RNA level of at least 20000 copies/mL and CD4 cell count of 0.05 to 0.40 x 10(9)/L. Patients were initially randomized to receive 1 of 3 antiretroviral regimens: indinavir, 800 mg every 8 hours; zidovudine, 200 mg every 8 hours and lamivudine, 150 mg every 12 hours; or all 3 drugs. After at least 24 weeks of blinded therapy, all patients received open-label 3-drug therapy. Antiretroviral activity was assessed by changes in HIV RNA level and CD4 cell count from baseline. Data through 100 weeks were summarized. Simultaneous initiation of indinavir, zidovudine, and lamivudine suppressed HIV RNA in 78% (25/32) of contributing patients to less than 50...Continue Reading

Citations

Dec 24, 1998·Lancet·J S MontanerM O'Shaughnessy
Sep 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Elisabetta BianchiAntonello Pessi
Aug 31, 2001·American Journal of Public Health·B R SchackmanK A Freedberg
Oct 23, 2002·Journal of General Internal Medicine·Carol E GolinNeil S Wenger
Jan 1, 2000·Sexually Transmitted Infections·G R KaufmannD A Cooper
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·U WintergerstB H Belohradsky
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·T N KakudaC V Fletcher
Mar 20, 2008·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Gregory S ZaricDouglas K Owens
Jun 19, 2008·Annals of Internal Medicine·Gillian D SandersDouglas K Owens
Sep 5, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jody LawrenceJohn D Baxter
Feb 15, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S L BeckerUNKNOWN Collaborations in HIV Outcomes Research--US (CHORUS) Program Team
Nov 6, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·J ServaisR Hemmer
Jun 8, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·P PezzottiUNKNOWN Italian Seroconversion Study
May 15, 2002·The Pediatric Infectious Disease Journal·Jean ServaisJean-Claude Schmit
Jun 17, 1999·AIDS·P R HarriganJ S Montaner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.